Molecular Biosystems Acquisition Builds Alliance's Cardiac Imaging Portfolio
This article was originally published in The Gray Sheet
Executive Summary
Alliance Pharmaceutical's acquisition of Molecular Biosystems, Inc. for $10.2 mil. in stock will expand its existing ultrasound cardiac imaging agent portfolio to include royalties for Optison.
You may also be interested in...
Photogen Buys Alliance’s Imagent To Build Cardiovascular Imaging Franchise
Photogen Technologies' acquisition of Alliance Pharmaceutical's medical imaging assets provides a cardiovascular market entry at least three years ahead of the company's own internal R&D program
Photogen Buys Alliance’s Imagent To Build Cardiovascular Imaging Franchise
Photogen Technologies' acquisition of Alliance Pharmaceutical's medical imaging assets provides a cardiovascular market entry at least three years ahead of the company's own internal R&D program
Alliance Touts Imagent Synthetic Heart Imaging Agent As Easier To Store
Alliance Pharmaceutical Corp. will launch its Imagent ultrasound heart imaging agent at the American Society of Echocardiography meeting in Orlando June 9-12